The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Gaining Confidence With a Switching Study

September 23rd 2022, 1:28pm


Sonia T. Oskouei, PharmD, BCMAS, DPLA, navigates the impact of the VOLTAIRE-X study, the only published switching study for adalimumab, on biosimilar uptake.

Multiple Pegfilgrastim Administration Options Allows for Patient-Centric Model of Care

September 20th 2022, 8:46pm


With 6 pegfilgrastim biosimilars approved, and multiple administration options, a patient-centric model of pegfilgrastim administration should be possible for patients with cancer who require prophylaxis of febrile neutropenia.

Evaluation of Biosimilar Trastuzumab MYL-1401O in HER2-Positive Breast Cancer

September 14th 2022, 7:00pm


The authors evaluate the effect and safety of biosimilar trastuzumab MYL-1401O in human epidermal growth factor receptor 2 (HER2)–positive early-stage (neoadjuvant and adjuvant therapy) and metastatic (palliative therapy) breast cancer using real-world data.

Practices Have to Grapple With the Logistics of Insurers’ Preferred Biosimilars: Dr Lalan Wilfong

September 11th 2022, 12:45pm


While commercial payers have been engaged with the shift to biosimilars, they all have their own preferred biosimilar, which makes it challenging for practices, explained Lalan Wilfong, MD, vice president of payer relations & practice transformation at The US Oncology Network.

Specialty Drug Trend Is Strong but May Shift With Biosimilars

September 8th 2022, 9:22pm


In 2021, the specialty drug trend rebounded from the pandemic, and it is expected to stay strong with more specialty drugs coming. Increased availability of biosimilars could shift this trend.

The Biosimilar Conversion Journey Went Through 2 Phases at Minnesota Oncology

September 4th 2022, 3:01pm


While initially there was a need for education around biosimilars, now there is a need to keep an eye on the evolving biosimilar marketplace and update the formulary of biosimilar medicines, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.

Gap After OCM May Cause Some Practices to Switch From Biosimilars to Brand Drugs

September 1st 2022, 1:53pm


The 1-year gap after the end of the Oncology Care Model (OCM) means some practices have to make hard decisions regarding cost of care or the financial health of the practice, explained Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network.

Provider and Payer Demand Largely Drives Biosimilar Adoption to Institution Formularies

August 29th 2022, 12:59pm


Having a biosimilar on formulary makes it more likely the biosimilar will be adopted. Length of time a biosimilar is on market can impact how likely it is to be added to formulary.

High-Concentration Version of Adalimumab Biosimilar Will Be Available in 2023

August 23rd 2022, 4:00pm


The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already approved. Both versions will launch in July 2023.

How Health Care Institutions Can Leverage Biosimilars to Generate Savings

August 17th 2022, 5:00pm


On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.